Company intelligence / Profile preview

Pharyx

Woburn, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Pharyx demonstrated on-demand biopharmaceutical production using miniature cell culture microbioreactors. MIT scientists published results in Nature Communications showing the system could produce either human growth hormone or interferon depending on nutrient inputs to genetically engineered yeast cells[1].

Therapeutic areas: Dermatology
Modalities: Biologic
Industry: Biotech

Partnerships

Defense Advanced Research Projects Agency (DARPA)Massachusetts Institute of Technology (MIT)

Beyond the preview

Go deeper on Pharyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharyx.

Explore the full profile